LOREN GOLDEN: Open Payments
NPI 1184353815 · CUMMING, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$591 in 25 payments from 17 companies in 2025. Trend: 2023 $258 · 2024 $255 · 2025 $591
Food & beverage: $591
| Company | Payments | Amount |
|---|---|---|
| Galderma Laboratories, L.P. | 1 | $82 |
| Novartis Pharmaceuticals Corporation | 3 | $67 |
| CVRx, Inc. | 1 | $62 |
| Amgen Inc. | 3 | $50 |
| Merck Sharp & Dohme LLC | 2 | $46 |
| Alnylam Pharmaceuticals Inc. | 2 | $45 |
| ABBVIE INC. | 2 | $34 |
| Actelion Pharmaceuticals US, Inc. | 2 | $33 |
| Edwards Lifesciences Corporation | 1 | $27 |
| Lilly USA, LLC | 1 | $25 |
Products named: LEQVIO, Barostim Neo System, REPATHA, VERQUVO, AMVUTTRA, VRAYLAR, SAPIEN 3 Ultra RESILIA, ZEPBOUND.
Industry payments across GA — which companies pay providers there.
